.svg)
.svg)
Ascendia Pharmaceuticals®, a leading specialty CDMO with a decade of proven formulation solutions, is excited to announce its attendance at the upcoming Controlled Release Society (CRS) Annual Meeting in Las Vegas.
By Robert Bloder
The event, taking place from July 24th to 28th, is a premier gathering for professionals from academia and industry across the globe working in the field of controlled release technologies. Ascendia's participation in this conference highlights its commitment to solving complex formulation challenges associated with a variety of delivery methods and offerings to yield the cutting-edge solutions to pharmaceutical companies working with all dosage forms.
Why Visit Ascendia®
Visitors to Ascendia Pharmaceuticals’ booth (#406) will learn how Ascendia has established itself as a frontrunner in the pharmaceutical CDMO industry. CRS focuses specifically on challenging formulations and issues related to controlled release of drugs. This aligns perfectly with Ascendia's enabling platform technologies and track record of providing solutions for unmet medical needs. By attending this event, Ascendia aims to connect with industry professionals seeking innovative formulation solutions that enhance persistence, compliance, and overall patient outcomes.
The Controlled Release Society Annual Meeting serves as an ideal platform for Ascendia to highlight its capabilities and expertise in the field of controlled release technologies. Ascendia specializes in achieving optimal bioavailability, solubility, and stability - the three key factors crucial for a successful controlled release product. Whether it's sterile or non-sterile products, oral solids, injectables, vaccines, or gene therapy, Ascendia's proficiency covers a wide range of formulation expertise across all modalities.
Ascendia Pharmaceuticals has a strong focus on lipid nanoparticles (LNPs), which play a vital role in advanced drug delivery systems. Ascendia is proud to be the only CDMO in North America equipped with the three essential LNP equipment for development, optimization, and GMP manufacturing. This unique advantage ensures continuity, consistency, and reliable results throughout the formulation and manufacturing processes, which is critical for successful controlled release product launch into market.
Innovation Showcase Presentation
Ascendia has been selected to give a presentation titled "Accelerating Drug Development Through Nanotechnologies" at the Innovation Showcase during the CRS Annual Meeting. This prestigious opportunity allows Ascendia to present its technologies, including LipidSol, NanoSol, and AmorSol, and demonstrate why pharmaceutical companies should choose Ascendia as their CDMO partner to enhance their product portfolios and pipelines. Innovation Showcase presenters are selected based upon merit, as topics are reviewed and accepted. Earning a presentation slot reflects Ascendia's expertise and commitment to innovation.
On July 24th, Ascendia will be presenting at the Innovation Showcase in the Concorde Room between 5 pm and 7 pm. This presentation is a must-attend for professionals interested in accelerating drug development and/or facing challenging controlled-release formulations.
Don't miss the opportunity to connect with Ascendia Pharmaceuticals' executive leadership team at the Controlled Release Society Annual Meeting to learn about our expertise and technologies. More specifically, Ascendia's expertise in providing innovative formulation solutions, especially in LNP technology, sets it apart as a leader in the industry. Visit booth number 406 to explore how Ascendia can help you overcome formulation challenges and optimize your product development from pre-formulation development and clinical to commercialization .
Reach out to Ascendia during the conference to start a conversation about your project and unlock the potential for success. You can also contact us to schedule a visit.
